Thanks for posting that Gf, in that article it stated "According...

Thanks for posting that Gf, in that article it stated
"According to Allied Market Research, theglobal ALS market size was valued at US$662.3m in 2022 and is projected to reach US$1,038.94m by 2032, growing at a compounded average growth rate (CAGR) of 4.6%."

Further research shows Amylyx's Relyvrio with a market in the US only were in this position.

How many patients are on Relyvrio?

about 4,000 patients

Since then, about 4,000 patients in the United States have received the treatment, a powder that is mixed with water and either drunk or ingested through a feeding tube. Its list price was $158,000 a year.4 Apr 2024

That equates to $632,000,000 US. And in the USA ONLY

Relyvrio was "Fast tract" in the US due to public pressure. In their stage 3 trial it was show to the same results as the placebo and consequently with draw from market. Not to mention the terrible side effects that resulted in many patients not continuing with the drug.

Further on global size from here https://www.researchnester.com/reports/motor-neuron-disease-treatment-market/3781
States " MND Treatment Market size Valued @ USD 9.5 and poised to reach USD 19.5 Billion by the end of 2036"

Anyway DYOR,
Good luck to all